However, a 2017 study which investigated the impact of mutations in JAK2, TET2, and ASXL1 genes on thrombotic risk in 587 patients with PV [14] found that TET2 or ASXL1 mutations (detected in 18% and 11% of patients, respectively) did not impact arterial nor venous thrombosis [14], although this was not a case-control study. The gene discussed is TET2; the disease is Venous thrombosis.